share_log

Candel Therapeutics to Present at the Jefferies Global Healthcare Conference

Candel Therapeutics to Present at the Jefferies Global Healthcare Conference

Candel Therapeutics將出席傑富瑞全球醫療保健大會
GlobeNewswire ·  05/22 20:00

NEEDHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, Candel's President and Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 5:30 p.m. ET.

馬薩諸塞州尼德姆,2024年5月22日(GLOBE NEWSWIRE)——專注於開發多模式生物免疫療法以幫助患者抗擊癌症的臨床階段生物製藥公司Candel Therapeutics, Inc.(Candel或公司)(納斯達克股票代碼:CADL)今天宣佈,Candel總裁兼首席執行官FMedSci醫學博士、博士保羅·彼得·塔克將在會上介紹公司概況傑富瑞全球醫療保健會議將於美國東部時間2024年6月5日星期三下午 5:30 舉行。

A live webcast of the presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors section on Candeltx.com. A replay of the webcast will be archived for up to 90 days following the session date.

在CandelTX.com的 “投資者” 部分選擇 “新聞與事件” 選項卡下的 “活動和演示”,即可觀看演示文稿的網絡直播。網絡直播的重播將在會議結束後最長存檔90天。

About Candel Therapeutics

關於坎德爾療法

Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable PDAC (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1b clinical trial in recurrent high-grade glioma (rHGG). Finally, Candel's enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

Candel是一家臨床階段的生物製藥公司,專注於開發現成的多模式生物免疫療法,以激發個性化的全身抗腫瘤免疫反應,幫助患者對抗癌症。Candel已分別基於新型轉基因腺病毒和單純皰疹病毒(HSV)基因結構建立了兩個臨床階段的多模態生物免疫治療平台。CAN-2409 是腺病毒平台的主要候選產品,目前正在進行非小細胞肺癌 (NSCLC)(第 2 期)、臨界可切除的 PDAC(第 2 期)和局部非轉移性前列腺癌(2 期和 3 期)的臨床試驗。CAN-3110 是 HSV 平台的主要候選產品,目前正在進行一項由研究者贊助的複發性高級別神經膠質瘤 (rHGG) 的 1b 期臨床試驗。最後,Candel的Enlighten發現平台是一個基於HSV的系統、迭代的發現平台,利用人類生物學和高級分析爲實體瘤創造新的病毒免疫療法。

For more information about Candel, visit: .

有關坎德爾的更多信息, 訪問:.

Forward-Looking Statements

前瞻性陳述

This press release includes certain disclosures that contain "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data; and expectations regarding the therapeutic benefit of the Company's programs. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; the Company's ability to continue as a going concern; expectations regarding the therapeutic benefit of the Company's programs; that final data from the Company's pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company's ability to efficiently discover and develop product candidates; the Company's ability to obtain and maintain regulatory approval of product candidates; the Company's ability to maintain its intellectual property; the implementation of the Company's business model, including strategic plans for the Company's business and product candidates; and other risks identified in the Company's filings with the U.S. Securities and Exchange Commission (SEC) including the Company's most recent Quarterly Report on Form 10-Q filed with the SEC and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as of the hereof date and should not be relied upon as representing its views as of any subsequent date.

本新聞稿包含經修訂的1995年《私人證券訴訟改革法》所指的 “前瞻性陳述” 的某些披露,包括但不限於有關開發計劃時間和進展的明示或暗示陳述,包括額外數據的時間和可用性;以及對公司計劃治療效益的預期。“可能”、“將”、“可能”、“應該”、“預期”、“計劃”、“預測”、“打算”、“相信”、“估計”、“預測”、“項目”、“潛力”、“繼續”、“目標” 等詞語旨在識別前瞻性陳述,儘管並非所有前瞻性陳述都包含這些識別詞。本新聞稿中的任何前瞻性陳述均基於管理層當前的預期和信念,並受許多風險、不確定性和重要因素的影響,這些風險和不確定性可能導致實際事件或結果與本新聞稿中包含的任何前瞻性陳述所表達或暗示的存在重大差異,包括但不限於與發展計劃的時機和進展相關的風險和不確定性;公司持續經營的能力;對治療收益的預期公司計劃;公司臨床前研究和已完成臨床試驗的最終數據可能與正在進行的研究和試驗中報告的中期數據存在重大差異;公司有效發現和開發候選產品的能力;公司獲得和維持監管部門對候選產品的批准的能力;公司維護其知識產權的能力;公司商業模式的實施,包括公司業務和候選產品的戰略計劃;以及其他風險在公司向美國證券交易委員會(SEC)提交的文件中確定,包括公司向美國證券交易委員會(SEC)提交的最新10-Q表季度報告以及隨後向美國證券交易委員會提交的文件。公司提醒您不要過分依賴任何前瞻性陳述,這些陳述僅代表其發表之日。公司不承擔任何義務公開更新或修改任何此類陳述,以反映預期或任何此類陳述所依據的事件、條件或情況的任何變化,或者可能影響實際業績與前瞻性陳述中列出的業績不同的可能性。本新聞稿中包含的任何前瞻性陳述僅代表公司截至本新聞稿發佈之日的觀點,自本新聞稿發佈之日起,不應將其作爲其觀點的依據,也不應被用來代表其自以後的任何日期的觀點。

Investor Contact
Theodore Jenkins
VP Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com

投資者聯繫人
西奧多·詹金斯
投資者關係和業務發展副總裁
Candel Therapeutics, In
tjenkins@candeltx.com

Media Contact:
Kyle Evans
ICR Westwicke
CandelPR@westwicke.com

媒體聯繫人:
凱爾·埃文斯
ICR Westwicke
CandelPR@westwicke.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論